BEIJING, Jan 18 (Reuters): China's Sinovac Biotech said on Monday that a clinical trial in Brazil showed its Covid-19 vaccine was almost 20 percentage points more effective in a small sub-group of patients who received their two doses longer apart.
The protection rate for 1,394 participants who received doses of either CoronaVac or placebo three weeks apart was nearly 70%, a Sinovac spokesman said.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.